                </a></li></ul></div><p><strong>Figure 3.  <span>Histopathological characterization of the MPD induced by JAK2 V617F.</span></strong></p><a id="article1.body1.sec3.sec3.fig1.caption1.p1" name="article1.body1.sec3.sec3.fig1.caption1.p1"></a><p>(A–C): Hematoxylin and eosin stains (magnification 500×) of BM (A), spleen (B), and liver (C) from representative polycythemic recipients of JAK2 V617F-transduced BM.</p>
<a id="article1.body1.sec3.sec3.fig1.caption1.p2" name="article1.body1.sec3.sec3.fig1.caption1.p2"></a><p>In the spleen, a lymphoid follicle (f) and an area of erythroid hyperplasia (e) are indicated.</p>
<a id="article1.body1.sec3.sec3.fig1.caption1.p3" name="article1.body1.sec3.sec3.fig1.caption1.p3"></a><p>The same tissues from recipients of JAK2 WT-transduced BM showed no pathological changes compared with normal controls (data not shown).</p>
<a id="article1.body1.sec3.sec3.fig1.caption1.p4" name="article1.body1.sec3.sec3.fig1.caption1.p4"></a><p>(D) Wright-Giemsa stains (top panels) and acetylcholinesterase stains (bottom panels) of purified megakaryocytes from recipients of JAK2 V617F-transduced BM (right panels) or normal control mice (left panels).</p>
<a id="article1.body1.sec3.sec3.fig1.caption1.p5" name="article1.body1.sec3.sec3.fig1.caption1.p5"></a><p>Note the preponderance of small megakaryocytes from JAK2 V617F recipients, some of which are undergoing proplatelet formation (arrowheads), accompanied by abnormal mitoses with low apparent ploidy (insert).</p>
<a id="article1.body1.sec3.sec3.fig1.caption1.p6" name="article1.body1.sec3.sec3.fig1.caption1.p6"></a><p>(E) Flow cytometric analysis of BM and spleen from a representative recipient of JAK2 V617F-transduced BM, stained with the indicated hematopoietic lineage antigens.</p>
<a id="article1.body1.sec3.sec3.fig1.caption1.p7" name="article1.body1.sec3.sec3.fig1.caption1.p7"></a><p>The mean fluorescence intensity of GFP expressed from JAK2 retroviral provirus was reproducibly and significantly lower than the GFP fluorescence of a comparable BCR-ABL retrovirus (data not shown).</p>
<a id="article1.body1.sec3.sec3.fig1.caption1.p8" name="article1.body1.sec3.sec3.fig1.caption1.p8"></a><p>Note the shift of GFP<sup>+/lo</sup> erythropoiesis (TER-119<sup>+</sup>) from BM to spleen and the expression of GFP in low abundance CD41<sup>+</sup> megakaryocytes.</p>
<a id="article1.body1.sec3.sec3.fig1.caption1.p9" name="article1.body1.sec3.sec3.fig1.caption1.p9"></a><p>(F) Flow cytometric assessment of erythrocyte differentiation <a href="#pone.0000018-Socolovsky1">[47]</a>, assessed by expression of transferrin receptor (CD71) and TER-119 in splenocytes of recipients of JAK2 WT-transduced (top) and JAK2 V617F-transduced (bottom) BM.</p>
<a id="article1.body1.sec3.sec3.fig1.caption1.p10" name="article1.body1.sec3.sec3.fig1.caption1.p10"></a><p>Note the increased (3.5-fold) population of CD71<sup>+/lo</sup>TER-119<sup>+</sup> erythroblasts in JAK2 V617F recipients.</p>
